Sasmit Sarangi
Overview
Explore the profile of Sasmit Sarangi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quon R, Sarangi S, Rogg J, Villamar M
R I Med J (2013)
. 2023 May;
106(5):38-39.
PMID: 37195160
No abstract available.
2.
Mondia M, Kritselis M, Donahue J, Elinzano H, Sarangi S, Bryant D, et al.
Front Neurol
. 2023 Jan;
13:1017087.
PMID: 36703629
Purpose: Epithelioid glioblastoma is an unusual histologic variant of malignant glioma. The present study investigates both the genomic and transcriptomic determinants that may promote the development of this tumor. Methods:...
3.
Ahrendsen J, Sehgal K, Sarangi S, Uhlmann E, Varma H, Arnason J, et al.
J Hematol
. 2021 Nov;
10(5):212-216.
PMID: 34804310
Chimeric antigen receptor (CAR) T-cell therapy targeting cluster of differentiation (CD)19 has had a transformative impact on patient outcomes in a subset of patients with relapsed/refractory non-Hodgkin lymphoma. We present...
4.
Cole S, Sarangi S, Einstein D, McMasters M, Alterman R, Bruce J, et al.
Surg Neurol Int
. 2021 Jul;
12:237.
PMID: 34221568
Background: Parkinsonism is a rare complication of non-germinomatous germ cell tumors (NGGCTs) arising from the pineal region. Case Description: We describe a 23-year-old man who presented with Parinaud syndrome, fatigue,...
5.
Sarangi S, Mosulpuria K, Higgins M, Bardia A
Curr Breast Cancer Rep
. 2014 Nov;
6(3):146-153.
PMID: 25431637
Circulating Tumor cells (CTCs) represent tumor cells in the blood stream dislodged from the primary tumor. The presence of CTCs in the bloodstream provides a unique opportunity to sample cancer...
6.
Pandey A, Sarangi S, Chien K, Sengupta P, Papa A, Basu S, et al.
Nanotechnology
. 2014 Oct;
25(44):445101.
PMID: 25302488
Tumor vasculature is critically dependent on platelet mediated hemostasis and disruption of the same can augment delivery of nano-formulation based chemotherapeutic agents which depend on enhanced permeability and retention for...
7.
Reynolds K, Sarangi S, Bardia A, Dizon D
Pharmgenomics Pers Med
. 2014 Apr;
7:95-105.
PMID: 24715764
Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody,...
8.
Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, et al.
Cancer Res
. 2013 Oct;
74(3):675-685.
PMID: 24121494
Nanomedicines that preferentially deploy cytotoxic agents to tumors and molecular targeted therapeutics that inhibit specific aberrant oncogenic drivers are emerging as the new paradigm for the management of cancer. While...
9.
Papa A, Sidiqui A, Balasubramanian S, Sarangi S, Luchette M, Sengupta S, et al.
Cell Oncol (Dordr)
. 2013 Oct;
36(6):449-57.
PMID: 24081907
Purpose: Nanoencapsulation of chemotherapeutics is an established method to target breast tumors and has been shown to enhance the efficacy of therapy in various animal models. During the past two...
10.
Sarangi S, Pandey A, Papa A, Sengupta P, Kopparam J, Dadwal U, et al.
Med Oncol
. 2013 Apr;
30(2):567.
PMID: 23568163
Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has...